Aileron Therapeutics, Inc Garners $40,000,000 Series D Round

  • Feed Type
  • Date
    6/8/2009
  • Company Name
    Aileron Therapeutics, Inc
  • Mailing Address
    840 Memorial Drive, 2nd Floor Cambridge, MA 02139
  • Company Description
    Aileron Therapeutics is an emerging biopharmaceutical company that is applying its proprietary cell permeable peptide technology to generate breakthrough therapeutics
    for the treatment of cancer and other diseases. Aileron’s technology is the first and
    only process that allows peptides to penetrate cells in a sequence-independent manner. Aileron is developing the first generation of peptide therapeutics directed at intra-cellular protein-protein interaction targets that are not addressable by small molecule or biological drugs.
  • Website
    http://www.aileronrx.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $40,000,000
  • Transaction Round
    Series D
  • Proceeds Purposes
    Proceeds from the financing will be used to advance Aileron’s lead Stapled Peptide program toward clinical trials in 2010 and to further advance the Stapled Peptide platform and programs in oncology, immune/inflammation, metabolic disease, and infectious disease.
  • M&A Terms
  • Venture Investor
    SR One
  • Venture Investor
    GlaxoSmithKline
  • Venture Investor
    Excel Medical Fund
  • Venture Investor
    Apple Tree Partners
  • Venture Investor
    Novartis Venture Fund
  • Venture Investor
    Lilly Ventures
  • Venture Investor
    Roche Venture Fund

By posting a comment, you agree to our terms and conditions.